Oral News and Research

RSS

U.N. agencies, Rotary International launch mass polio immunization campaign in Central Africa

The WHO, UNICEF and Rotary International on Thursday announced they will kick off a "mass polio immunization campaign in three Central African nations" on Friday "in response to a polio outbreak suspected in more than 100 deaths and deemed 'unusual' because it targets adults more than children," the Associated Press reports.

14 Nov 2010

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Results of two pre-specified sub-study analyses of the 18,113 patient RE-LY trial, involving the newly approved oral anticoagulant Pradaxa (dabigatran etexilate mesylate) capsules, will be presented at the American Heart Association's Annual Scientific Sessions on Monday, November 15, 2010.

12 Nov 2010

Drug industry roundup: Fosamax trial focuses scrutiny on osteoporosis drugs; What about $4 generics; Recalls undermining confidence

The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.

12 Nov 2010

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Reata Pharmaceuticals today announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes. The data will be presented in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference to be held November 16-21, 2010, in Denver, Colorado.

12 Nov 2010

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

Agenta Biotechnologies, Inc., a private biotechnology company, announced that it has received a $1.1 million grant from the National Institutes of Health and National Institute of Dental and Craniofacial Research (NIH/NIDCR) for the further development of a biologically activated membrane to improve soft tissue healing associated with oral surgery.

12 Nov 2010

Study finds arsenic improves survival rate in APL patients

Arsenic, a toxic compound with a reputation as a good tool for committing homicide, has a significant positive effect on the survival of patients with acute promyelocytic leukemia (APL), when administered after standard initial treatment, according to a new, multi-center study led by a researcher at Wake Forest University Baptist Medical Center.

12 Nov 2010

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

11 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

NIST develops new Vaccinium berry suite of standard reference materials

National Institute of Standards and Technology (NIST) researchers have developed new certified reference materials for measuring amounts of organic acids in dietary supplements formulated with Vaccinium berries-cranberries, blueberries and bilberries. As described in a recent paper, manufacturers and researchers can use this new suite of standard reference materialsTM (SRMs) as quality assurance tools.

11 Nov 2010

New insect control method can bring decline in malaria-bearing mosquitoes

Research carried out in Mali, West Africa, has demonstrated that a new, safe and uncomplicated insect control method, developed at the Hebrew University of Jerusalem, can bring about a serious decline in malaria-bearing mosquitoes in afflicted regions in the world.

11 Nov 2010

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).

11 Nov 2010

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced its financial results in accordance with International Financial Reporting Standards (IFRS) for the first nine months of 2010, which ended on 30 September 2010.

11 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

Lemon-lime soft drink could improve effectiveness of oral anticancer drug: Study

Experiments with an artificial stomach suggest that a popular lemon-lime soft drink could play an unexpected role in improving the effectiveness of an oral anticancer drug. The experiments produced evidence that patients will absorb more of the unnamed drug, tested in Phase I in clinical trials, when taken with "flat" or degassed Sprite. The study appears in ACS' Molecular Pharmaceutics, a bi-monthly journal.

11 Nov 2010

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced that data from two separate pre-clinical research studies were published in the December issue of Molecular Oral Microbiology.

10 Nov 2010

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

10 Nov 2010

Gentium to present three abstracts on Defibrotide at American Society of Hematology

Gentium S.p.A. today announced that three abstracts on Defibrotide will be presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology to be held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

10 Nov 2010

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Hemispherx Biopharma, Inc. announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its Ampligen and Alferon development programs.

10 Nov 2010

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).

10 Nov 2010

TRU-016 abstracts to be presented at ASH meeting

Emergent BioSolutions Inc. today announced the acceptance of four abstracts for presentation at the 52nd Annual Meeting of the American Society of Hematology to be held from December 4 to 7 in Orlando, Florida. The presentations include an oral presentation on the results of a Phase I dose escalation, monotherapy study of TRU-016 for patients with chronic lymphocytic leukemia.

10 Nov 2010

Oral News and Research

U.N. agencies, Rotary International launch mass polio immunization campaign in Central Africa

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Drug industry roundup: Fosamax trial focuses scrutiny on osteoporosis drugs; What about $4 generics; Recalls undermining confidence

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

Study finds arsenic improves survival rate in APL patients

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NIST develops new Vaccinium berry suite of standard reference materials

New insect control method can bring decline in malaria-bearing mosquitoes

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Lemon-lime soft drink could improve effectiveness of oral anticancer drug: Study

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Gentium to present three abstracts on Defibrotide at American Society of Hematology

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

TRU-016 abstracts to be presented at ASH meeting

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News